Brief: Merus NV To Pay Genmab $240 Million Termination Fee Under Certain Conditions If Deal Falls Through - SEC Filing
Sept 29 (Reuters) - SEC Filing: MERUS NV: IF DEAL IS TERMINATED UNDER SOME CIRCUMSTANCES, CO TO PAY GENMAB A TERMINATION FEE OF $240 MILLION - SEC FILING MERUS NV: IF DEAL IS TERMINATED UNDER SOME CIRCUMSTANCES, GENMAB TO PAY REGULATORY TERMINATION FEE OF $416 MILLION TO CO- SEC FILING Source text: [ID:n0001193125-25-221807] Further company coverage: 2GH.F ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genmab A/S
See all newsBrief: Genmab Says Orbis Investment Management Holds 4.99% Of Genmab Voting Rights As Of June 12
Brief: Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Brief: Genmab Presents Epcore Fl-1 Data Showing Consistent Efficacy, Safety For Epcoritamab Combination
Brief: Genmab Says Orbis Investment Management Limited Holds 5.08% Of Genmab A/S As Of May 8, 2026
Genmab falls after 'uneventful' Q1, profit miss